BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 32023736)

  • 1. [Eltrombopag for the treatment of primary immune thrombocytopenia in 23 pediatric patients].
    Huang YT; Liu XF; Chen YF; Fu RF; Liu W; Xue F; Zhang L; Yang RC
    Zhonghua Xue Ye Xue Za Zhi; 2019 Dec; 40(12):1031-1034. PubMed ID: 32023736
    [No Abstract]   [Full Text] [Related]  

  • 2. [Efficacy and safety of eltrombopag in the treatment of primary immune thrombocytopenia: real-world data from a single medical center].
    Dong XF; Li YL; Li NB; Lin WN; Wang T; Wang HQ; Li LJ; Qu W; Xing LM; Liu H; Wu YH; Wang GJ; Song J; Guan J; Wang XM; Shao ZH; Fu R
    Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):271-276. PubMed ID: 38716599
    [No Abstract]   [Full Text] [Related]  

  • 3. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
    Grainger JD; Locatelli F; Chotsampancharoen T; Donyush E; Pongtanakul B; Komvilaisak P; Sosothikul D; Drelichman G; Sirachainan N; Holzhauer S; Lebedev V; Lemons R; Pospisilova D; Ramenghi U; Bussel JB; Bakshi KK; Iyengar M; Chan GW; Chagin KD; Theodore D; Marcello LM; Bailey CK
    Lancet; 2015 Oct; 386(10004):1649-58. PubMed ID: 26231455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study.
    Bussel JB; de Miguel PG; Despotovic JM; Grainger JD; Sevilla J; Blanchette VS; Krishnamurti L; Connor P; David M; Boayue KB; Matthews DC; Lambert MP; Marcello LM; Iyengar M; Chan GW; Chagin KD; Theodore D; Bailey CK; Bakshi KK
    Lancet Haematol; 2015 Aug; 2(8):e315-25. PubMed ID: 26688484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spotlight on eltrombopag in pediatric ITP in China: a long-term observational study in real-world practice.
    Cheng X; Fu L; Ma J; Gu H; Chen Z; Zhao L; Wang X; Wu R
    Blood Adv; 2021 Oct; 5(19):3799-3806. PubMed ID: 34605871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice.
    González-López TJ; Alvarez-Román MT; Pascual C; Sánchez-González B; Fernández-Fuentes F; Jarque I; Pérez-Rus G; Pérez-Crespo S; Bernat S; Hernández-Rivas JA; Andrade MM; Cortés M; Gómez-Nuñez M; Olivera P; Martínez-Robles V; Fernández-Rodríguez A; Fuertes-Palacio MA; Fernández-Miñano C; de Cabo E; Fisac R; Aguilar C; Bárez A; Peñarrubia MJ; García-Frade LJ; González-Porras JR
    Eur J Haematol; 2016 Sep; 97(3):297-302. PubMed ID: 26709028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eltrombopag in pediatric chronic and refractory ITP: data from a retrospective multicenter study from Lebanon.
    Noun P; Inati A; Raffoul R; Younes JA; Mardini J; Khalife H
    Ann Hematol; 2022 May; 101(5):991-997. PubMed ID: 35278100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study.
    Wong RSM; Saleh MN; Khelif A; Salama A; Portella MSO; Burgess P; Bussel JB
    Blood; 2017 Dec; 130(23):2527-2536. PubMed ID: 29042367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia].
    Huang YT; Liu XF; Chen YF; Fu RF; Liu W; Zhang L; Yang RC
    Zhonghua Xue Ye Xue Za Zhi; 2018 Jan; 39(1):32-36. PubMed ID: 29551030
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial.
    Bussel JB; Provan D; Shamsi T; Cheng G; Psaila B; Kovaleva L; Salama A; Jenkins JM; Roychowdhury D; Mayer B; Stone N; Arning M
    Lancet; 2009 Feb; 373(9664):641-8. PubMed ID: 19231632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Maintenance of efficacy and its predictors after discontinuation of eltrombopag in adults with primary immune thrombocytopenia].
    Sun HP; You JH; Chen QS; Wang J; Li JM
    Zhonghua Xue Ye Xue Za Zhi; 2023 Jan; 44(1):32-37. PubMed ID: 36987720
    [No Abstract]   [Full Text] [Related]  

  • 12. Thrombopoietic agents for the treatment of persistent and chronic immune thrombocytopenia in children.
    Ramaswamy K; Hsieh L; Leven E; Thompson MV; Nugent D; Bussel JB
    J Pediatr; 2014 Sep; 165(3):600-5.e4. PubMed ID: 24857517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia.
    González-López TJ; Pascual C; Álvarez-Román MT; Fernández-Fuertes F; Sánchez-González B; Caparrós I; Jarque I; Mingot-Castellano ME; Hernández-Rivas JA; Martín-Salces M; Solán L; Beneit P; Jiménez R; Bernat S; Andrade MM; Cortés M; Cortti MJ; Pérez-Crespo S; Gómez-Núñez M; Olivera PE; Pérez-Rus G; Martínez-Robles V; Alonso R; Fernández-Rodríguez A; Arratibel MC; Perera M; Fernández-Miñano C; Fuertes-Palacio MA; Vázquez-Paganini JA; Gutierrez-Jomarrón I; Valcarce I; de Cabo E; Sainz A; Fisac R; Aguilar C; Paz Martínez-Badas M; Peñarrubia MJ; Calbacho M; de Cos C; González-Silva M; Coria E; Alonso A; Casaus A; Luaña A; Galán P; Fernández-Canal C; Garcia-Frade J; González-Porras JR
    Am J Hematol; 2015 Mar; 90(3):E40-3. PubMed ID: 25400215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy and safety of rhTPO in the treatment of pediatric primary immune thrombocytopenia].
    Huang Y; Liu X; Xue F; Chen Y; Liu W; Fu R; Zhang L; Yang R
    Zhonghua Xue Ye Xue Za Zhi; 2015 Jun; 36(6):511-4. PubMed ID: 26134019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice.
    Ptushkin VV; Vinogradova OY; Pankrashkina MM; Chernikov MV; Arshanskaya EG; Tkachenko NE
    Ter Arkh; 2018 Aug; 90(7):70-76. PubMed ID: 30701925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of eltrombopag in treatment-refractory primary immune thrombocytopenia: a retrospective study.
    Eser A; Toptas T; Kara O; Sezgin A; Noyan-Atalay F; Yilmaz G; Ozgumus T; Pepedil-Tanrikulu F; Kaygusuz-Atagunduz I; Firatli-Tuglular T
    Blood Coagul Fibrinolysis; 2016 Jan; 27(1):47-52. PubMed ID: 26258668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dental procedures in 24 patients with chronic immune thrombocytopenia in prospective clinical studies of eltrombopag.
    Tarantino MD; Fogarty PF; Shah P; Brainsky A
    Platelets; 2015; 26(1):93-6. PubMed ID: 24433306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Multi-Center Study on the Efficacy of Eltrombopag in Management of Refractory Chronic Immune Thrombocytopenia: A Real-Life Experience.
    Çekdemir D; Güvenç S; Özdemirkıran F; Eser A; Toptaş T; Özkocaman V; Haydaroğlu Şahin H; Ermiş Turak E; Esen R; Cömert M; Sadri S; Aslaner M; Uncu Ulu B; Karakuş A; Selim Bapur D; Alacacıoğlu İ; Aydın D; Tekinalp A; Namdaroğlu S; Ceran F; Tarkun P; Kiper D; Çetiner M; Yenerel M; Demir AM; Yılmaz G; Terzi H; Atilla E; Malkan ÜY; Acar K; Öztürk E; Tombak A; Sunu C; Salim O; Alayvaz N; Sayan Ö; Ozan Ü; Ayer M; Gökgöz Z; Andıç N; Kızılkılıç E; Noyan F; Özen M; Pepedil Tanrıkulu F; Alanoğlu G; Özkan HA; Aslan V; Çetin G; Akyol Erikçi A; Deveci B; Ersoy Dursun F; Dermenci H; Aytan P; Gündüz M; Karakuş V; Özlü C; Demircioğlu S; Akay Yanar OM; Özatlı D; Ündar L; Tiftik EN; Türköz Sucak AG; Haznedaroğlu İ; Özcan M; Şencan M; Tombuloğlu M; Özet G; Bilgir O; Turgut B; Özcan MA; Payzın KB; Sönmez M; Ayyıldız O; Dal MS; Ertop Ş; Turgut M; Soysal T; Kaya E; Ünal A; Pehlivan M; Atagündüz I; Tuğlular Fıratlı T; Saydam G; Diz Küçükkaya R
    Turk J Haematol; 2019 Nov; 36(4):230-237. PubMed ID: 31327186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of eltrombopag for patients 65 years old or older with immune thrombocytopenia.
    González-López TJ; Sánchez-González B; Jarque I; Bernat S; Fernández-Fuertes F; Caparrós I; Soto I; Fernández-Rodríguez A; Bolaños E; Pérez-Rus G; Pascual C; Hernández-Rivas JA; López-Ansoar E; Gómez-Nuñez M; Martínez-Robles V; Olivera P; Yera Cobo M; Peñarrubia MJ; Fernández-Miñano C; de Cabo E; Martínez Badas MP; Perdomo G; García-Frade LJ
    Eur J Haematol; 2020 Mar; 104(3):259-270. PubMed ID: 31840311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of eltrombopag for secondary immune thrombocytopenia in clinical practice.
    González-López TJ; Alvarez-Román MT; Pascual C; Sánchez-González B; Fernández-Fuentes F; Pérez-Rus G; Hernández-Rivas JA; Bernat S; Bastida JM; Martínez-Badas MP; Martínez-Robles V; Soto I; Olivera P; Bolaños E; Alonso R; Entrena L; Gómez-Nuñez M; Alonso A; Yera Cobo M; Caparrós I; Tenorio M; Arrieta-Cerdán E; Lopez-Ansoar E; García-Frade J; González-Porras JR
    Br J Haematol; 2017 Sep; 178(6):959-970. PubMed ID: 28573819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.